Mr. Weisman is an accomplished entrepreneur in the life sciences industry. Mr. Weisman is currently the CEO of Seventh Sense Biosystems, a health technology company developing a breakthrough painless diagnostic blood collection platform. Prior to joining Seventh Sense, he was the founder, chairman, and CEO of EKR Therapeutics, a specialty pharmaceutical company focused on the hospital critical care market. He also co-founded ESP Pharma, where he served as a director as well as the company’s president and chief operating officer until its sale to PDL Biopharma in 2005.
Mr. Weisman began his career in sales and marketing at Merck & Co., later moving to Parke-Davis where he launched that company’s diabetes franchise in 1997. He graduated with a BA in chemistry from Rutgers University.
Partner at Polaris
Dr. Nashat (PhD) is a Partner in Polaris’ Boston office. He joined Polaris in 2002 and focuses on investments in healthcare.
Dr. Nashat currently represents Polaris as a Director of AgBiome, aTyr Pharmaceuticals (NASDAQ: LIFE), Fate Therapeutics (NASDAQ: FATE), Jnana Therapeutics , Marauder Therapeutics , Metacrine Therapeutics, Morphic Therapeutic, Olivo Labs, Promedior Pharmaceuticals, Scholar Rock, Selecta Biosciences (NASDAQ: SELB), Sofregen Medical, Syros Pharmaceuticals (NASDAQ: SYRS) and TARIS Biomedical.
Prior to joining Polaris, he completed his PhD as a Hertz Fellow in Chemical Engineering at the Massachusetts Institute of Technology with a minor in Biology under the guidance of Dr. Robert Langer. Dr. Nashat also earned both his MS and BS in Materials Science and Mechanical Engineering at the University of California, Berkeley. He has been named to the Forbes Midas List of “Top 100 Venture Capitalists.”
S. Douglas Sheldon
Executive Chairman, Indochina Healthcare Ltd.
Mr. Sheldon is an accomplished entrepreneur and pharmaceutical executive with over 30 years of global experience. He currently serves as the Executive Chairman of the Board of Directors at Indochina Healthcare Ltd., a Bangkok-based, regionally focused specialty Pharma and medical device company which he founded in 1994. Mr. Sheldon co-founded EKR Therapeutics, a specialty pharmaceutical company focused on the hospital critical care market, ESP Pharma, a start-up which was successfully commercialized and later acquired by PDL BioPharma, and ESP Equity Partners, where he is the Managing Partner.
His previous experience includes senior level executive positions at Warner Lambert, Parke Davis and Pfizer. During his 17-year career at Pfizer, Mr. Sheldon held positions of Country Manager/CEO and Regional Vice President for Asia.
Mr. Sheldon earned MBA degree from Syracuse University and BS in Chemistry from LeMoyne College. He served as a Lt. Commander in the US Navy and is bilingual in English/Spanish.